Illumina Inc.
Prezzo: 160.97Società e modello di business
Illumina Inc. specializes in genomic sequencing and analysis, providing tools and services for genetic research and diagnostics. Its core products include sequencing systems, reagents, and software for data analysis. Major business segments encompass research and clinical applications, with primary revenue sources derived from sales of sequencing instruments and consumables, as well as service agreements. The company serves a diverse clientele, including academic institutions, pharmaceutical companies, and healthcare providers.
Profilo di investimento
The investment profile of Illumina Inc. is more aligned with growth investors, given its focus on innovation in genomic technology and potential for market expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income, as it does not currently offer dividends. The company's recent performance indicates moderate volatility, suggesting a balanced approach may be prudent for investors.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 5.54 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -5.9% ↓
- Sorpresa EPS
- 9.5% meglio del previsto
- Volatilità 20g
- 2.4% stabile
Impatto della previsione
positivoTraccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-05 02:40 | Compra | Mantieni | Weak fundamentals with mixed momentum signals. |
| 2026-05-28 02:47 | Mantieni | Compra | Strong momentum, but revenue decline raises concerns. |
| 2026-05-08 15:03 | — | Mantieni | Mixed momentum; fundamentals show some weakness. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-06-01 11:27 | Guggenheim | Target alzato | 170 → 180 | 162.96 |
| 2026-05-14 20:23 | RBC Capital | Aggiorna | — → 170 | 143.24 |
| 2026-05-14 09:05 | Daiwa | Rating migliorato | — → 155 | 145 |
Ancora nulla